Dicerna Pharmaceuticals Inc. started an underwritten public offering of 6,150,000 common shares.
The Cambridge, Mass-based biotechnology company will give the underwriters an option to buy up to an additional 922,500 shares.
Net proceeds will be used to fund preclinical studies and clinical trials for products in the pipeline. The company will use the remainder of any net proceeds for continued technology platform development, working capital and general corporate purposes.
Citigroup, Leerink Partners and Stifel are acting as the joint book-running managers for the offering, with H.C. Wainwright & Co. and SunTrust Robinson Humphrey as the lead co-managers.
Dicerna Pharmaceuticals develops treatments for diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases.